Precision Biosciences (DTIL) Stock
Gene editing biotech firm developing disease treatments. Here's the price, business snapshot, and what's worth knowing about Precision Biosciences in October 2026.
Precision BioSciences is a biotechnology company developing gene-editing therapies using its proprietary ARCUS platform. ARCUS is a targeted nuclease technology designed to make precise DNA edits for potential treatments across oncology, genetic and rare diseases, and ex vivo cell therapies. The company runs early- to mid-stage programmes and may also pursue partnerships or licensing to advance candidates. With a market capitalisation around $82.4m, Precision BioSciences is a small-cap, development-stage firm: this can mean attractive upside if clinical or partnership news is positive, but also elevated risk, volatility and funding sensitivity. Key factors for investors include clinical trial readouts, regulatory feedback, intellectual property position, and cash runway. This summary is for educational purposes only — not personalised investment advice — and investors should carry out their own research, consider their risk tolerance and expect that biotech investments can decline as well as rise.
Why You’ll Want to Watch This Stock
ARCUS editing tech
A proprietary nuclease platform underpins the pipeline and partnerships; scientific progress matters, though outcomes and timelines can change.
Clinical catalysts ahead
Trial readouts and regulatory filings can drive meaningful share moves, but positive data is not guaranteed and setbacks are possible.
Small-cap dynamics
Market cap is modest, implying higher volatility and funding sensitivity; suitable for investors who accept higher risk and long horizons.
